Several tumor features were linked with a higher chance of pCR: no or low ER levels, low or no progesterone receptor levels, ...
COPERNICUS, a pragmatic phase 2b study of subcutaneous (SC) amivantamab (ami) + chemotherapy (chemo) with enhanced dermatologic adverse event (AE) prophylaxis in EGFR-mutated advanced NSCLC: Interim ...
Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results